Developer docs
API playgroundTry for free, no card

Search company profiles

Adimab

Full company profile

uuid00067xp

Namestring
Adimab
Legal namestring
Adimab, LLC
Websiteurl
adimab.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Adimab is a privately held therapeutic antibody discovery and engineering company founded in 2007 and headquartered in Lebanon, New Hampshire, with a secondary office in Mountain View, California. The company operates a proprietary yeast-based antibody discovery platform that delivers fully human IgGs, HCAbs (heavy chain-only antibodies), multispecifics, and TCRs by combining synthetic and immune libraries with integrated engineering and developability assessment. Its technology suite includes Chain Exchange (ChEx) for high-throughput bispecific generation, orthogonal CH1:Cκ interface designs for correct heavy/light chain pairing, a TCR-targeting VHH platform, structure-based CD3 engineering to decouple CD3 affinity from polyreactivity, ML-designed synthetic HCAb libraries, and an internal Atlas database linking 15+ years of experimental data across 1,431 programs and 2.85 million clones for ML-driven developability prediction.

The company runs a partnership-only, no-internal-pipeline business model serving pharmaceutical and biotechnology companies of all sizes across three engagement structures: Funded Discovery, where Adimab scientists execute programs on partners' behalf and deliver leads within roughly four months; Platform Transfer, where partner labs (GSK, Biogen, Novo Nordisk, Merck, Lilly, Takeda) internalize the yeast-based platform; and Non-Exclusive Programs, which license modular components such as CD3/CD28 binders and heterodimerization mutation sets to 20-25+ partners. Revenue is generated through research funding, upfront license fees, milestone payments, and royalties on programs that reach development and commercialization.

Adimab reports more than 140 biopharma partnerships, 675+ therapeutic programs, 90+ clinical-stage assets, and 6 commercial product approvals since inception (GSK's Exdensur/depemokimab, Innovent's TYVYT and SINTBILO, IASO Bio's FUCASO, Invivyd's PEMGARDA, Sun Pharma's UNLOXCYT). In 2024, the company established the Adimab Royalty Company (ARC) to house royalty rights from approximately 500 completed programs, creating a structure for shareholders to participate in either the operating company or the royalty portfolio. Adimab is led by Co-Founder and Executive Chairman Tillman U. Gerngross, PhD, CEO Philip Chase, President and CSO Eric Krauland, PhD, and CFO Ryan McGovern, with board representation from Polaris Partners, SV Health Investors, and Mithril Capital Management.

Short descriptiontext

Adimab is a private, partnership-based therapeutic antibody discovery and engineering company using a proprietary yeast-based platform to deliver IgGs, HCAbs, multispecifics, and TCRs for pharmaceutical and biotechnology partners, with 140+ partnerships and 6 commercial product approvals since 2007.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLebanon, United States
HQ citystring
Lebanon
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody discovery platform, therapeutic antibody engineering, yeast display libraries, bispecific antibody development, biologics discovery services
Industry3 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Therapeutic Antibody Discovery Services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Funded Discovery Partnerships
TypeProfessional Services
Description

Partners pay for antibody discovery and engineering services where Adimab scientists drive programs on partners' behalf. Revenue generated through research funding, milestone payments, and technology access fees. Within four months of project initiation, Adimab delivers high-quality leads and detailed data packages.

adimab.com
2Platform Transfer Licensing
TypeLicensing Royalties
Description

Transfer of proprietary yeast-based discovery platform to pharmaceutical partners for in-house operation. Partners receive training, ongoing support, and platform updates. GSK was the first Platform Transfer collaborator and internalized the technology for depemokimab development. Other collaborators include Biogen, Lilly, Merck, Novo Nordisk, and Takeda.

adimab.com
3Non-Exclusive Program Licensing
TypeLicensing Royalties
Description

Modular access to validated discovery and engineering modules (CD3/CD28 binders, heterodimerization solutions) without full platform integration. Partners pay for access to specific validated components. More than 25 partners have licensed CD3/CD28 technologies non-exclusively.

adimab.com
4Milestone and Royalty Payments
TypeLicensing Royalties
Description

Partners exercise commercial options and pay milestones as programs advance through development. In 2025, 10 partners exercised commercial options. Adimab has created the Adimab Royalty Company (ARC) to manage royalty rights from nearly 500 completed therapeutic programs. Partners have exercised more than 125 commercial licenses to option rights to advance programs into clinical development.

adimab.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Adimab operates a proprietary yeast-based antibody discovery and engineering platform that delivers therapeutic IgGs, HCAbs, multispecifics, TCRs, and T cell engagers to pharmaceutical and biotechnology partners. Services are delivered through three partnership models: Funded Discovery (Adimab scientists run partner-funded programs), Platform Transfer (licensing of the proprietary platform for in-house partner operation), and Non-Exclusive Programs (modular access to validated components such as CD3/CD28 binders and heterodimerization solutions).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 90 clinical programs initiated by partners
+7 more records
Product overview1 text field

Adimab offers a unified therapeutic antibody discovery and engineering platform consisting of proprietary yeast-based technologies for antibody discovery, engineering, and multispecific construction. The core platform delivers IgGs, HCAbs, and multispecifics with emphasis on developability. Key products include the Antibody Discovery Platform (synthetic and immune yeast libraries), Antibody Engineering services, Multispecific Antibodies and T Cell Engagers (with proprietary CD3/CD28 binders and ChEx technology), and the Protein/TCR Engineering Platform. Modular add-ons include the TCE Toolkit (non-exclusive CD3/CD28 antibodies), Heterodimerization Solutions (orthogonal CH1:Cκ and CH3 mutations), and the Atlas Database (ML-powered data integration with 1,431 programs). Services are delivered through Funded Discovery (partner-funded discovery programs), Platform Transfer (in-house platform enablement), and Non-Exclusive Programs (plug-and-play modules). Six commercial products have been approved including GSK's Exdensur (depemokimab), Innovent's TYVYT and SINTBILO, IASO Bio's FUCASO, Invivyd's PEMGARDA, and Sun Pharma's UNLOXCYT.

Product and service7 records
1Antibody Discovery Platform
CategoryAntibody Discovery
Description

Proprietary yeast-based antibody discovery platform combining fully human synthetic and immune libraries to deliver therapeutic IgGs, HCAbs, and multispecifics that are highly specific, stable, and developable. Delivered to pharmaceutical and biotech partners as part of Funded Discovery, Platform Transfer, and Non-Exclusive Programs.

2Antibody Engineering and Optimization
CategoryAntibody Engineering
Description

Engineering services that transform antibody leads into high-affinity, highly developable candidates through guided engineering, ML-assisted developability prediction, and high-throughput screening. Used by partners across Funded Discovery and Platform Transfer engagements.

3Multispecific Antibodies and T Cell Engagers
CategoryMultispecific Antibody Engineering
Description

Bispecific and multispecific antibody engineering including proprietary solutions for Fc (HC:HC) and Fab (HC:LC) heterodimerization, the CD3/CD28 binder panel for T cell engagers, and Chain Exchange (ChEx) technology for high-throughput generation of correctly paired multispecifics. Delivered through Funded Discovery and Non-Exclusive Programs (CD3/CD28 components licensed non-exclusively to 25+ partners).

4Protein and TCR Engineering Platform
CategoryProtein Engineering
Description

Yeast-based protein engineering platform for therapeutic proteins and T cell receptors (TCRs). Includes dual-mode TCR-Fc expression, all-CDR diversification, deep mutational scanning, and AI-guided engineering for tailored binding, stability, and expression. Used for TCR-based therapeutics and other non-antibody protein scaffolds.

5Funded Discovery
CategoryDiscovery Services
Description

Partner-funded antibody discovery and optimization service in which Adimab scientists execute programs on the partner's behalf. Delivers panels of diverse IgG and/or HCAb proteins with full characterization data within approximately four months of project initiation, transferring leads to the partner for advancement to the clinic.

6Platform Transfer
CategoryTechnology Licensing
Description

Structured technology licensing arrangement in which Adimab's proprietary yeast-based discovery platform is transferred to a partner's laboratory for in-house operation. Includes training, ongoing support, access to unique library diversities, and platform updates. Platform Transfer partners include GSK, Biogen, Novo Nordisk, Merck, Lilly, and Takeda, with partners having initiated 200+ internal programs.

7Non-Exclusive Programs
CategoryNon-Exclusive Licensing
Description

Modular access to Adimab's validated discovery and engineering modules — including characterized CD3 and CD28 antibodies in IgG and VHH formats, and CH1:Ckappa/CH3 heterodimerization mutation sets — without full platform integration. Licensed non-exclusively; trusted by 20+ partners.

Scale indicator19 records

Each record includes

Type, Value, Description, Source

Partnership55 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

GSK was Adimab's first Platform Transfer collaborator, internalizing Adimab's proprietary yeast-based technology for antibody discovery, optimization, production, and characterization. GSK used the platform for depemokimab development, achieving regulatory approvals in the EU, China, US, Japan, and UK. GSK continues to use the Adimab platform to support other internal programs. Depemokimab is the first approved product from Adimab's Platform Transfer model.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Platform Transfer collaborator with Adimab technology transferred and implemented at their facility. Biogen has exercised commercial options including in 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Platform Transfer collaborator with Adimab technology transferred and implemented at their facility for internal antibody discovery programs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Platform Transfer collaborator with Adimab technology transferred and implemented at their facility for internal antibody discovery programs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Platform Transfer collaborator with Adimab technology transferred and implemented at their facility. Also a funded discovery partner with expanded collaboration in 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Platform Transfer collaborator with Adimab technology transferred and implemented at their facility for internal antibody discovery programs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Funded discovery partner with expanded collaboration in 2025. Partnership for therapeutic antibody discovery programs.

8Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Funded discovery partner for therapeutic antibody discovery programs.

adimab.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Funded discovery partner. Two commercial products from partnership: TYVYT (sintilimab) approved in China for multiple cancers, and SINTBILO (tafolecimab) approved for hypercholesterolemia.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Funded discovery partner with commercial options exercised in 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Funded discovery partner with expanded collaboration in 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Funded discovery partner for therapeutic antibody discovery programs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

New alliance established in 2025.

14Central Therapeutics
Strategic tierMinorTypeStrategic or Co-development Partner
Description

New alliance established in 2025.

adimab.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

New alliance established in 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Early-stage venture-backed partner for antibody therapeutics development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Early-stage venture-backed partner with expanded collaboration and commercial options exercised.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Early-stage venture-backed partner with commercial options exercised in 2024 and 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnered for discovery and optimization of TTX-080, an HLA-G antibody that advanced into clinical trials for solid tumors.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Early-stage venture-backed partner with new clinical programs in 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mid-size public biopharmaceutical company partner for antibody therapeutics development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mid-size public biopharmaceutical company with expanded collaboration in 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mid-size public biopharmaceutical company partner for antibody therapeutics development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Expanded collaboration in 2025.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Expanded collaboration in 2025.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Expanded collaboration in 2025.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Expanded collaboration in 2025.

28iTeos
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mid-size public biopharmaceutical company partner with new clinical programs in 2025.

adimab.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner with new clinical programs in 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner with commercial product PEMGARDA (pemivibart) authorized for emergency use in the US for COVID-19 prophylaxis.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner with new clinical programs in 2025, including commercial options exercised.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Early-stage venture-backed partner with commercial options exercised.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner with commercial options exercised in 2025.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner with commercial options exercised in 2025.

35Bambusa
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner with commercial options exercised in 2025.

adimab.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner with commercial options exercised in 2025.

37Meiji Seika Pharma
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner with commercial options exercised in 2025.

adimab.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner with commercial options exercised in 2024.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner with commercial options exercised in 2024.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

New alliance established in 2025.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

New alliance established in 2025.

42Onco3R
Strategic tierMinorTypeStrategic or Co-development Partner
Description

New alliance established in 2025.

adimab.com
43Biotheus
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner advancing PM-1080, an EGFR × cMET bispecific antibody incorporating Adimab's CH1-Cκ heterodimerization technology, into Phase III trials for colorectal cancer and NSCLC.

adimab.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner logo displayed on partnering page.

45Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner logo displayed on partnering page.

adimab.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner logo displayed on partnering page.

47Sun Pharma
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner with commercial product UNLOXCYT (cosibelimab) approved in the US for cutaneous squamous cell carcinoma.

adimab.com
48IASO Bio
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner with commercial product FUCASO (equecabtagene autoleucel) approved in China for multiple myeloma.

adimab.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Expanded collaboration in 2024.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

New alliance established in 2024.

51Incendia Therapeutics
Strategic tierMinorTypeStrategic or Co-development Partner
Description

New alliance established in 2024.

adimab.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

New alliance established in 2024.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

New alliance established in 2024.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic medical center partner logo displayed on partnering page.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic medical center partner logo displayed on partnering page.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Atreca
TypeEmerging player
Description

Clinical-stage biotech using its immune repertoire capture technology for antibody discovery, with partnership and internal programs. Comparable discovery technology stack aimed at biopharma partners.

TypeEmerging player
Description

AI-driven biologics discovery platform using generative AI and high-throughput wet lab to design antibodies. Emerging AI-first competitor to established platforms like Adimab in therapeutic antibody discovery partnerships.

TypeDirect peer
Description

Danish antibody therapeutics company with proprietary platforms (DuoBody, HexaBody, etc.) enabling bispecific and next-gen antibody creation. Comparable in building partner-friendly antibody technologies and generating approved products (Darzalex, etc.) through platform-based deals.

TypeBroad incumbent
Description

Large CRO with biologics discovery capabilities including antibody discovery through its CDMO and research services divisions. Broader incumbent offering Adimab-relevant services as part of a much larger CRO portfolio.

TypeBroad incumbent
Description

Global biologics CRO/CDMO offering antibody discovery, development, and manufacturing services. Broader portfolio incumbent competing with Adimab in antibody discovery services for global biopharma partners.

TypeEmerging player
Description

AI protein language model company developing foundation models for protein design including therapeutic applications. Adjacent emerging AI-native player competing for partner interest in computational antibody design.

TypeDirect peer
Description

Antibody discovery company providing in vitro display-based antibody libraries and engineering for therapeutic partners. Direct competitor focused on discovery services without internal pipeline, similar to Adimab's partnership-only model.

TypeDirect peer
Description

Public antibody discovery platform using single-cell screening and proprietary technology for therapeutic antibody discovery and engineering. Directly competes with Adimab for biopharma partnership deals, offering an alternative discovery engine with similar partnership-based GTM.

9Harbour BioMed
TypeDirect peer
Description

Biopharma with proprietary H2L2 and HCAb transgenic mouse platforms plus antibody discovery/engineering services. Closely comparable to Adimab in offering antibody discovery partnerships across multiple therapeutic areas with heavy codeveloping/partnership focus.

TypeEmerging player
Description

AI-native antibody design company combining ML with high-throughput wet-lab testing. Emerging AI-driven alternative that could compete with Adimab's yeast-based platform by offering faster in silico lead generation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers18 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adimab

Therapeutic Antibody Discovery Servicesadimab.com

Adimab is a private, partnership-based therapeutic antibody discovery and engineering company using a proprietary yeast-based platform to deliver IgGs, HCAbs, multispecifics, and TCRs for pharmaceutical and biotechnology partners, with 140+ partnerships and 6 commercial product approvals since 2007.

What Adimab does

Adimab is a privately held therapeutic antibody discovery and engineering company founded in 2007 and headquartered in Lebanon, New Hampshire, with a secondary office in Mountain View, California. The company operates a proprietary yeast-based antibody discovery platform that delivers fully human IgGs, HCAbs (heavy chain-only antibodies), multispecifics, and TCRs by combining synthetic and immune libraries with integrated engineering and developability assessment. Its technology suite includes Chain Exchange (ChEx) for high-throughput bispecific generation, orthogonal CH1:Cκ interface designs for correct heavy/light chain pairing, a TCR-targeting VHH platform, structure-based CD3 engineering to decouple CD3 affinity from polyreactivity, ML-designed synthetic HCAb libraries, and an internal Atlas database linking 15+ years of experimental data across 1,431 programs and 2.85 million clones for ML-driven developability prediction.

The company runs a partnership-only, no-internal-pipeline business model serving pharmaceutical and biotechnology companies of all sizes across three engagement structures: Funded Discovery, where Adimab scientists execute programs on partners' behalf and deliver leads within roughly four months; Platform Transfer, where partner labs (GSK, Biogen, Novo Nordisk, Merck, Lilly, Takeda) internalize the yeast-based platform; and Non-Exclusive Programs, which license modular components such as CD3/CD28 binders and heterodimerization mutation sets to 20-25+ partners. Revenue is generated through research funding, upfront license fees, milestone payments, and royalties on programs that reach development and commercialization.

Adimab reports more than 140 biopharma partnerships, 675+ therapeutic programs, 90+ clinical-stage assets, and 6 commercial product approvals since inception (GSK's Exdensur/depemokimab, Innovent's TYVYT and SINTBILO, IASO Bio's FUCASO, Invivyd's PEMGARDA, Sun Pharma's UNLOXCYT). In 2024, the company established the Adimab Royalty Company (ARC) to house royalty rights from approximately 500 completed programs, creating a structure for shareholders to participate in either the operating company or the royalty portfolio. Adimab is led by Co-Founder and Executive Chairman Tillman U. Gerngross, PhD, CEO Philip Chase, President and CSO Eric Krauland, PhD, and CFO Ryan McGovern, with board representation from Polaris Partners, SV Health Investors, and Mithril Capital Management.

Adimab firmographics

Firmographics
Name
Adimab
Legal name
Adimab, LLC
Website
https://adimab.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Adimab is a private, partnership-based therapeutic antibody discovery and engineering company using a proprietary yeast-based platform to deliver IgGs, HCAbs, multispecifics, and TCRs for pharmaceutical and biotechnology partners, with 140+ partnerships and 6 commercial product approvals since 2007.
Ownership category
akta.pro rank

Adimab industry classification

Industry
Product category
Therapeutic Antibody Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody discovery platform
  • Therapeutic antibody engineering
  • Yeast display libraries
  • Bispecific antibody development
  • Biologics discovery services

Where Adimab is headquartered

Location

Headquarters

HQ city
Lebanon
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Adimab business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Funded Discovery Partnerships: Partners pay for antibody discovery and engineering services where Adimab scientists drive programs on partners' behalf. Revenue generated through research funding, milestone payments, and technology access fees. Within four months of project initiation, Adimab delivers high-quality leads and detailed data packages.
  2. Platform Transfer Licensing: Transfer of proprietary yeast-based discovery platform to pharmaceutical partners for in-house operation. Partners receive training, ongoing support, and platform updates. GSK was the first Platform Transfer collaborator and internalized the technology for depemokimab development. Other collaborators include Biogen, Lilly, Merck, Novo Nordisk, and Takeda.
  3. Non-Exclusive Program Licensing: Modular access to validated discovery and engineering modules (CD3/CD28 binders, heterodimerization solutions) without full platform integration. Partners pay for access to specific validated components. More than 25 partners have licensed CD3/CD28 technologies non-exclusively.
  4. Milestone and Royalty Payments: Partners exercise commercial options and pay milestones as programs advance through development. In 2025, 10 partners exercised commercial options. Adimab has created the Adimab Royalty Company (ARC) to manage royalty rights from nearly 500 completed therapeutic programs. Partners have exercised more than 125 commercial licenses to option rights to advance programs into clinical development.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Adimab product offering

Product offering

Core offering

Adimab operates a proprietary yeast-based antibody discovery and engineering platform that delivers therapeutic IgGs, HCAbs, multispecifics, TCRs, and T cell engagers to pharmaceutical and biotechnology partners. Services are delivered through three partnership models: Funded Discovery (Adimab scientists run partner-funded programs), Platform Transfer (licensing of the proprietary platform for in-house partner operation), and Non-Exclusive Programs (modular access to validated components such as CD3/CD28 binders and heterodimerization solutions).

Product overview

Adimab offers a unified therapeutic antibody discovery and engineering platform consisting of proprietary yeast-based technologies for antibody discovery, engineering, and multispecific construction. The core platform delivers IgGs, HCAbs, and multispecifics with emphasis on developability. Key products include the Antibody Discovery Platform (synthetic and immune yeast libraries), Antibody Engineering services, Multispecific Antibodies and T Cell Engagers (with proprietary CD3/CD28 binders and ChEx technology), and the Protein/TCR Engineering Platform. Modular add-ons include the TCE Toolkit (non-exclusive CD3/CD28 antibodies), Heterodimerization Solutions (orthogonal CH1:Cκ and CH3 mutations), and the Atlas Database (ML-powered data integration with 1,431 programs). Services are delivered through Funded Discovery (partner-funded discovery programs), Platform Transfer (in-house platform enablement), and Non-Exclusive Programs (plug-and-play modules). Six commercial products have been approved including GSK's Exdensur (depemokimab), Innovent's TYVYT and SINTBILO, IASO Bio's FUCASO, Invivyd's PEMGARDA, and Sun Pharma's UNLOXCYT.

Differentiator

Problem solved

Functional benefit

Products and services

  • Antibody Discovery Platform Proprietary yeast-based antibody discovery platform combining fully human synthetic and immune libraries to deliver therapeutic IgGs, HCAbs, and multispecifics that are highly specific, stable, and developable. Delivered to pharmaceutical and biotech partners as part of Funded Discovery, Platform Transfer, and Non-Exclusive Programs.
  • Antibody Engineering and Optimization Engineering services that transform antibody leads into high-affinity, highly developable candidates through guided engineering, ML-assisted developability prediction, and high-throughput screening. Used by partners across Funded Discovery and Platform Transfer engagements.
  • Multispecific Antibodies and T Cell Engagers Bispecific and multispecific antibody engineering including proprietary solutions for Fc (HC:HC) and Fab (HC:LC) heterodimerization, the CD3/CD28 binder panel for T cell engagers, and Chain Exchange (ChEx) technology for high-throughput generation of correctly paired multispecifics. Delivered through Funded Discovery and Non-Exclusive Programs (CD3/CD28 components licensed non-exclusively to 25+ partners).
  • Protein and TCR Engineering Platform Yeast-based protein engineering platform for therapeutic proteins and T cell receptors (TCRs). Includes dual-mode TCR-Fc expression, all-CDR diversification, deep mutational scanning, and AI-guided engineering for tailored binding, stability, and expression. Used for TCR-based therapeutics and other non-antibody protein scaffolds.
  • Funded Discovery Partner-funded antibody discovery and optimization service in which Adimab scientists execute programs on the partner's behalf. Delivers panels of diverse IgG and/or HCAb proteins with full characterization data within approximately four months of project initiation, transferring leads to the partner for advancement to the clinic.
  • Platform Transfer Structured technology licensing arrangement in which Adimab's proprietary yeast-based discovery platform is transferred to a partner's laboratory for in-house operation. Includes training, ongoing support, access to unique library diversities, and platform updates. Platform Transfer partners include GSK, Biogen, Novo Nordisk, Merck, Lilly, and Takeda, with partners having initiated 200+ internal programs.
  • Non-Exclusive Programs Modular access to Adimab's validated discovery and engineering modules — including characterized CD3 and CD28 antibodies in IgG and VHH formats, and CH1:Ckappa/CH3 heterodimerization mutation sets — without full platform integration. Licensed non-exclusively; trusted by 20+ partners.

Quantifiable outcome

  • 90 clinical programs initiated by partners
  • +7 more outcomes

Companies that use Adimab

Customer profile

Named customers18 records

Segments4 records

Ideal customer profiles4 records

Adimab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature10 records

Adimab partnerships and signals

Strategic signal

Partnerships

55 partnerships are on record, tiered flagship, core and minor.

  • GSKflagshipStrategic or Co-development Partner · 15 April 2026GSK was Adimab's first Platform Transfer collaborator, internalizing Adimab's proprietary yeast-based technology for antibody discovery, optimization, production, and characterization. GSK used the platform for depemokimab development, achieving regulatory approvals in the EU, China, US, Japan, and UK. GSK continues to use the Adimab platform to support other internal programs. Depemokimab is the first approved product from Adimab's Platform Transfer model.
  • BiogencoreStrategic or Co-development PartnerPlatform Transfer collaborator with Adimab technology transferred and implemented at their facility. Biogen has exercised commercial options including in 2025.
  • Novo NordiskcoreStrategic or Co-development PartnerPlatform Transfer collaborator with Adimab technology transferred and implemented at their facility for internal antibody discovery programs.
  • MerckcoreStrategic or Co-development PartnerPlatform Transfer collaborator with Adimab technology transferred and implemented at their facility for internal antibody discovery programs.
  • LillycoreStrategic or Co-development PartnerPlatform Transfer collaborator with Adimab technology transferred and implemented at their facility. Also a funded discovery partner with expanded collaboration in 2025.
  • TakedacoreStrategic or Co-development PartnerPlatform Transfer collaborator with Adimab technology transferred and implemented at their facility for internal antibody discovery programs.
  • AlnylamcoreStrategic or Co-development PartnerFunded discovery partner with expanded collaboration in 2025. Partnership for therapeutic antibody discovery programs.
  • Bristol Myers SquibbcoreStrategic or Co-development PartnerFunded discovery partner for therapeutic antibody discovery programs.
  • InnoventcoreStrategic or Co-development PartnerFunded discovery partner. Two commercial products from partnership: TYVYT (sintilimab) approved in China for multiple cancers, and SINTBILO (tafolecimab) approved for hypercholesterolemia.
  • NovartiscoreStrategic or Co-development PartnerFunded discovery partner with commercial options exercised in 2025.
  • RegeneroncoreStrategic or Co-development PartnerFunded discovery partner with expanded collaboration in 2025.
  • VertexcoreStrategic or Co-development PartnerFunded discovery partner for therapeutic antibody discovery programs.
  • RoivantcoreStrategic or Co-development PartnerNew alliance established in 2025.
  • Central TherapeuticsminorStrategic or Co-development PartnerNew alliance established in 2025.
  • Enara BiominorStrategic or Co-development PartnerNew alliance established in 2025.
  • DragonflycoreStrategic or Co-development PartnerEarly-stage venture-backed partner for antibody therapeutics development.
  • NextPoint TherapeuticscoreStrategic or Co-development PartnerEarly-stage venture-backed partner with expanded collaboration and commercial options exercised.
  • Santa Ana BiocoreStrategic or Co-development PartnerEarly-stage venture-backed partner with commercial options exercised in 2024 and 2025.
  • Tizona TherapeuticscoreStrategic or Co-development PartnerPartnered for discovery and optimization of TTX-080, an HLA-G antibody that advanced into clinical trials for solid tumors.
  • Kelonia TherapeuticscoreStrategic or Co-development PartnerEarly-stage venture-backed partner with new clinical programs in 2025.
  • AlectorcoreStrategic or Co-development PartnerMid-size public biopharmaceutical company partner for antibody therapeutics development.
  • Cullinan TherapeuticscoreStrategic or Co-development PartnerMid-size public biopharmaceutical company with expanded collaboration in 2025.
  • Scholar RockcoreStrategic or Co-development PartnerMid-size public biopharmaceutical company partner for antibody therapeutics development.
  • 3T BiosciencesminorStrategic or Co-development PartnerExpanded collaboration in 2025.
  • CompugenminorStrategic or Co-development PartnerExpanded collaboration in 2025.
  • RedRidgeminorStrategic or Co-development PartnerExpanded collaboration in 2025.
  • Therini BiominorStrategic or Co-development PartnerExpanded collaboration in 2025.
  • iTeoscoreStrategic or Co-development PartnerMid-size public biopharmaceutical company partner with new clinical programs in 2025.
  • AbogencoreStrategic or Co-development PartnerPartner with new clinical programs in 2025.
  • InvivydcoreStrategic or Co-development PartnerPartner with commercial product PEMGARDA (pemivibart) authorized for emergency use in the US for COVID-19 prophylaxis.
  • Triveni BiocoreStrategic or Co-development PartnerPartner with new clinical programs in 2025, including commercial options exercised.
  • WerewolfcoreStrategic or Co-development PartnerEarly-stage venture-backed partner with commercial options exercised.
  • SixPeaks BiocoreStrategic or Co-development PartnerPartner with commercial options exercised in 2025.
  • Montis BiosciencesminorStrategic or Co-development PartnerPartner with commercial options exercised in 2025.
  • BambusaminorStrategic or Co-development PartnerPartner with commercial options exercised in 2025.
  • IkaikaminorStrategic or Co-development PartnerPartner with commercial options exercised in 2025.
  • Meiji Seika PharmaminorStrategic or Co-development PartnerPartner with commercial options exercised in 2025.
  • REGiMMUNEminorStrategic or Co-development PartnerPartner with commercial options exercised in 2024.
  • NextPoint TherapeuticscoreStrategic or Co-development PartnerPartner with commercial options exercised in 2024.
  • Variant BiominorStrategic or Co-development PartnerNew alliance established in 2025.
  • TriptychminorStrategic or Co-development PartnerNew alliance established in 2025.
  • Onco3RminorStrategic or Co-development PartnerNew alliance established in 2025.
  • BiotheuscoreStrategic or Co-development PartnerPartner advancing PM-1080, an EGFR × cMET bispecific antibody incorporating Adimab's CH1-Cκ heterodimerization technology, into Phase III trials for colorectal cancer and NSCLC.
  • BioNTechcoreStrategic or Co-development PartnerPartner logo displayed on partnering page.
  • Boehringer IngelheimcoreStrategic or Co-development PartnerPartner logo displayed on partnering page.
  • Janssen PharmaceuticalscoreStrategic or Co-development PartnerPartner logo displayed on partnering page.
  • Sun PharmacoreStrategic or Co-development PartnerPartner with commercial product UNLOXCYT (cosibelimab) approved in the US for cutaneous squamous cell carcinoma.
  • IASO BiocoreStrategic or Co-development PartnerPartner with commercial product FUCASO (equecabtagene autoleucel) approved in China for multiple myeloma.
  • iOmxminorStrategic or Co-development PartnerExpanded collaboration in 2024.
  • Candid TherapeuticsminorStrategic or Co-development PartnerNew alliance established in 2024.
  • Incendia TherapeuticsminorStrategic or Co-development PartnerNew alliance established in 2024.
  • Leyden LabsminorStrategic or Co-development PartnerNew alliance established in 2024.
  • Treeline BiosciencesminorStrategic or Co-development PartnerNew alliance established in 2024.
  • Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerAcademic medical center partner logo displayed on partnering page.
  • MD Anderson Cancer CentercoreStrategic or Co-development PartnerAcademic medical center partner logo displayed on partnering page.

Scale indicators19 records

Recent moves7 records

Expansion highlights6 records

Adimab competitors and assessment

Company assessment

Emerging players

  • Atreca: Clinical-stage biotech using its immune repertoire capture technology for antibody discovery, with partnership and internal programs. Comparable discovery technology stack aimed at biopharma partners.
  • Absci: AI-driven biologics discovery platform using generative AI and high-throughput wet lab to design antibodies. Emerging AI-first competitor to established platforms like Adimab in therapeutic antibody discovery partnerships.
  • EvolutionaryScale: AI protein language model company developing foundation models for protein design including therapeutic applications. Adjacent emerging AI-native player competing for partner interest in computational antibody design.
  • BigHat Biosciences: AI-native antibody design company combining ML with high-throughput wet-lab testing. Emerging AI-driven alternative that could compete with Adimab's yeast-based platform by offering faster in silico lead generation.

Direct peers

  • Genmab: Danish antibody therapeutics company with proprietary platforms (DuoBody, HexaBody, etc.) enabling bispecific and next-gen antibody creation. Comparable in building partner-friendly antibody technologies and generating approved products (Darzalex, etc.) through platform-based deals.
  • Specifica: Antibody discovery company providing in vitro display-based antibody libraries and engineering for therapeutic partners. Direct competitor focused on discovery services without internal pipeline, similar to Adimab's partnership-only model.
  • AbCellera Biologics: Public antibody discovery platform using single-cell screening and proprietary technology for therapeutic antibody discovery and engineering. Directly competes with Adimab for biopharma partnership deals, offering an alternative discovery engine with similar partnership-based GTM.
  • Harbour BioMed: Biopharma with proprietary H2L2 and HCAb transgenic mouse platforms plus antibody discovery/engineering services. Closely comparable to Adimab in offering antibody discovery partnerships across multiple therapeutic areas with heavy codeveloping/partnership focus.

Broad incumbents

  • Charles River Laboratories: Large CRO with biologics discovery capabilities including antibody discovery through its CDMO and research services divisions. Broader incumbent offering Adimab-relevant services as part of a much larger CRO portfolio.
  • WuXi Biologics: Global biologics CRO/CDMO offering antibody discovery, development, and manufacturing services. Broader portfolio incumbent competing with Adimab in antibody discovery services for global biopharma partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Adimab social profiles

Digital presence

Adimab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adimab leadership team

Management profile

Number of profiles

Profiles20 records

Adimab funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adimab M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adimab

What does Adimab do?

Adimab operates a proprietary yeast-based antibody discovery and engineering platform that delivers therapeutic IgGs, HCAbs, multispecifics, TCRs, and T cell engagers to pharmaceutical and biotechnology partners. Services are delivered through three partnership models: Funded Discovery (Adimab scientists run partner-funded programs), Platform Transfer (licensing of the proprietary platform for in-house partner operation), and Non-Exclusive Programs (modular access to validated components such as CD3/CD28 binders and heterodimerization solutions).

Is Adimab a public or private company?

Adimab is a private company. It is classified as venture growth investor backed and is currently operating.

When was Adimab founded?

Adimab was founded in 2007. It employs 101 to 250 people.

Where is Adimab based?

Adimab is headquartered in Lebanon, United States, in the North America region.

How does Adimab make money?

Four revenue lines are on record. Funded Discovery Partnerships are the primary driver. The others are platform Transfer Licensing, non-Exclusive Program Licensing and milestone and Royalty Payments.

Who are Adimab's main competitors?

Emerging players on record are Atreca, Absci, EvolutionaryScale and BigHat Biosciences. Direct peers are Genmab, Specifica, AbCellera Biologics and Harbour BioMed. Broad incumbents are Charles River Laboratories and WuXi Biologics.

Does Adimab have an API?

No public API is recorded for Adimab.

What industry is Adimab in?

Adimab's product category is Therapeutic Antibody Discovery Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAdimab Collaborator GSK Receives Additional Marketing Approval for DepemokimabGSK received marketing approvals from the European Commission and China's National Medical Products Administration for depemokimab, adding to prior approvals in the United States, Japan, and United Kingdom. Depemokimab is the first ultra-long-acting biologic product approved for its indicated conditions, featuring an extended half-life and engineered high binding affinity to enable twice-yearly dosing. The drug represents the sixth collaborator program to reach the market under Adimab's Platform Transfer model, with GSK having used Adimab's proprietary yeast-based technology for antibody discovery, optimization, and production.MorningstarAdimab Collaborator GSK Receives Additional Marketing Approval for DepemokimabGSK has received marketing approvals from the European Commission and China's National Medical Products Administration for depemokimab, an ultra-long-acting biologic that enables twice-yearly dosing, adding to prior approvals obtained in the United States, Japan, and the United Kingdom. Depemokimab is the first approved product to emerge from Adimab's Platform Transfer collaboration model, with the molecule engineered using Adimab's proprietary yeast-based antibody discovery and optimization technology. The milestone validates Adimab's technology transfer business model, as GSK internalized the platform to enable in-house antibody discovery, optimization, and production on any target of its choosing.Tracxn2026 Funding Rounds & List of InvestorsAdimab's funding rounds from 2007 to 2012 are listed, including Series A through Series F. The rounds show increasing post-money valuations, with the Series F round in April 2012 reaching a valuation of $45.78 million.ForbesThe Startup Building An Operating System For Biotech AITamarind Bio, a Y Combinator-incubated startup that builds software infrastructure enabling scientists to seamlessly use multiple AI models for drug discovery, announced it raised a $12 million Series A round led by Dimension Capital, bringing its total funding to $13.6 million. The company, which has been cash-flow positive since inception, counts pharmaceutical and biotech companies including Boehringer Ingelheim, Bayer, Mammoth Biosciences and Adimab among its customers. Tamarind Bio plans to use the funding to double its 12-person headcount and continue software development, having achieved 700% growth over the past year without a sales staff.PR NewswireAdimab Records Another Year of Double-Digit Clinical Program GrowthAdimab, a therapeutic antibody discovery company, announced that 11 new programs entered clinical trials in 2025, bringing its total to 89 partner programs that have entered clinical development. Six therapeutic products using molecules from its platform have been approved for commercial sale, including GSK's Exdensur and Innovent's TYVYT, and the company highlighted its royalty structure (ARC) created in 2024 to give shareholders flexibility to participate in its royalty portfolio or operating company. In 2025, 10 partners exercised commercial options and over 125 commercial licenses have been exercised to date.MorningstarAdimab Records Another Year of Double-Digit Clinical Program GrowthAdimab announced that 11 new programs entered clinical trials in 2025, bringing its total number of partner programs that have entered clinical trials to 89. Six therapeutic products containing molecules discovered or optimized using the Adimab platform have been approved for commercial sale, including GSK's Exdensur for severe asthma and Innovent's TYVYT for multiple cancers. The Adimab Royalty Company (ARC) is generating its first wave of revenue from royalties derived from nearly 500 completed therapeutic programs, providing shareholders flexibility to participate in the compounding value of the royalty portfolio or the operating company.YahooAdimab Records Another Year of Double-Digit Clinical Program GrowthAdimab announced that 11 new partner programs entered clinical trials in 2025, bringing its total clinical programs to 89, including six therapeutic products that have received regulatory approval for commercial sale across multiple markets. The six approved products span treatments for cancer, asthma, cardiovascular disease, and COVID-19, involving partners including GSK, Innovent, IASO Bio, Invivyd, and Sun Pharma. Adimab highlighted that the first wave of approvals is generating revenue for its newly created Adimab Royalty Company structure established in 2024.PR NewswireAdimab Reports Strong Partnering Year for 2025Adimab, LLC announced it entered into 23 partnership agreements and achieved 50 technical and development milestones in 2025, with 75 new therapeutic programs initiated. The company expanded collaborations with 12 existing partners including Alnylam, Lilly, and Regeneron, while establishing new alliances with companies such as Roivant, Central Therapeutics, and Enara Bio. Since 2009, Adimab has partnered with over 140 companies to generate more than 650 therapeutic programs, including 89 clinical programs and 6 approved products.